EMERGE: An Ehealth Model of Care for Paediatric Patients and Families at the End-of-Treatment for Acute Lymphoblastic Leukaemia

Not Applicable

Recruiting

• Conditions: Paediatric Acute Lymphoblastic Leukaemia; Lymphoblastic Lymphoma; Cancer - Children's - Leukaemia & Lymphoma; Public Health - Health service research

• Registration Number: ACTRN12623000761662
• Lead Sponsor: The Murdoch Children's Research Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-07-12
• Last Update Posted: 5 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Inclusion criteria for the patient participant group include:
- Aged between 2 and 18 years at the time of enrolment.
- Diagnosed with ALL or LLy.
- Received oncology treatment at the RCH or MCH.
- In the final 4 months of maintenance treatment or has completed treatment within the last 6 months.

Inclusion criteria for the parent/caregiver group include:
•Parent/caregiver of a patient aged between 2 to 18 years who has been treated for ALL/LLy at either the RCH or MCH and is in the maintenance phase or has completed treatment.

Inclusion criteria for clinical stakeholder group include:
•Medical, nursing, social work, allied health, mental health or paediatric integrated cancer service (PICS) staff who work with children treated for ALL/LLy and their families at either the RCH or MCH.

Exclusion Criteria

Exclusion criteria for the patient group include:
• Diagnosed with another form of cancer
• Relapsed or refractory disease
• Receiving end-of-life treatment

Exclusion criteria for the parent/caregiver group include:
•Parent/caregiver of a child with another form of cancer or who has relapsed or refractory disease and/or is receiving end-of-life treatment.

Exclusion criteria for clinical stakeholder group include:
•Medical, nursing, social work, allied health, mental health or PICS staff who do not work directly with paediatric patients with leukaemia.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reach measured as: <br>a) Percentage uptake among eligible families determined by study records<br>b) Representativeness of participants for Victorian ALL population as compared to Victorian state cancer registry[ Measured at the end of the trial];Effectiveness measured as:<br>a) Satisfaction with the clinical intervention measured via the Client Satisfaction Questionnaire (CSQ-8)<br>b) Experience of clinical care utilising a study specific Experience of Care Survey[ Measured post telehealth 1 and post telehealth 2.<br>];Adoption measured as:<br>a) Participation rates determined from study records of number of families approached.<br>b) Number of staff trained in Emerge delivery as determined from completion of the delegation log <br>[ Measured at the end of the trial.]